ClinicalTrials.gg
No longer availableNCT01206504Updated Feb 22, 2022

Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure

An expanded access record providing MGAWN1 in West Nile Virus Infection, sponsored by MacroGenics. No longer available. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2022-02-22.

Sponsored by MacroGenics · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Ages
8 Years and older
Sex
All
01

Study summary

This study will test an experimental drug called MGAWN1 for the treatment of West Nile infections.

Read the detailed description

The objective of this study is to provide expanded access to MGAWN1; the study is not intended for subjects who are eligible for and have access to non-expanded access protocols.

02

Conditions studied

  • West Nile Virus Infection

Keywords

  • West Nile virus
  • WNV
  • Encephalitis
  • Meningitis
  • Acute Flaccid Paralysis
  • Monoclonal Antibody
  • WNND
  • West Nile Neuroinvasive Disease
  • Accidental Exposure to West Nile Virus
03

In context

Encephalitis

125 studies on the registry are indexed under Encephalitis; 33 are open to participants now.

Browse Encephalitis studies →

Lead sponsor

MacroGenics is the lead sponsor of 42 studies on the registry; 4 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 11 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All

Eligibility criteria

Inclusion Criteria:

  1. For West Nile Neuroinvasive Disease subjects: Have neurological signs and/or symptoms of West Nile meningitis, encephalitis, and/or acute flaccid paralysis
  2. For subjects with suspected West Nile virus infection:

    • Receiving immunosuppressive treatment for any disease, such as diseases, or transplant recipients; or
    • Have received organs or tissues or cells from donors likely infected with West Nile virus (as shown by serology or PCR/NAT from the donor, organs, or tissues) or
    • Have acquired immunodeficiency (other than from immunosuppressive treatment or from receiving infected transplants) or congenital immunodeficiency
  3. For subjects with substantial exposure to West Nile virus: Exposure by any route, including percutaneous, inhalation, or mucosal exposure (such as might occur in a laboratory accident)
  4. Develop signs and/or symptoms within 14 days before study enrollment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Access details

Study type
Expanded access

Available treatment

  • BiologicalMGAWN1

    Humanized monoclonal to West Nile virus. Dose=30mg/kg

06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01206504
Lead sponsor
MacroGenics
Responsible party
Sponsor
First posted
Sep 22, 2010
Last update
Feb 22, 2022
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion